secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cadrenal Therapeutics, Inc. (CVKD)
CIK:        0001937993
Form:       8-K
Filed at:   2025-07-18T23:59:59+00:00
Accession:  0001213900-25-065710
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 5.08, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cadrenal director resigns; 2025 annual meeting set for Sept 24, proposal deadline July 28
--------------------------------------------------------------------------------

- Director Robert Lisicki resigned from board effective July 15, 2025, with no disagreement with the company.
- 2025 annual meeting scheduled for September 24, 2025; record date for voting is July 28, 2025.
- Shareholder proposals for proxy inclusion must be received by July 28, 2025; director nominations also due July 28.
- Universal proxy rule: shareholders soliciting proxies for director nominees must provide notice by July 28, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1937993/000121390025065710/0001213900-25-065710-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1937993/000121390025065710/ea0249594-8k_cadrenal.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-065710

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer